High Bleeding Risk 

Most contemporary DES studies continue to exclude or underrepresent patients for whom guideline-recommended DAPT was considered unsuitable and in many cases, this includes High Bleed Risk (HBR) patients.

The evolution of PCI practices and associated technologies over the last 40 years have enabled the treatment of increasingly complex patient populations. One such population comprises of patients at high bleeding risk (HBR).

Due to concerns around late thrombotic events, increases in DAPT were recommended. This created a considerable dilemma for DAPT treatment in patients considered to be HBR. Until recently, HBR patients were generally recommend treatment with bare metal stents (BMS), as shorter DAPT durations (sometimes as low as 1 month) were considered adequate at the time.

The SYNERGY™ stent is the only stent with a polymer (bioabsorbable or permanent) that has a High Bleed Risk CE Mark indication. Take some time to look at the information below, to see how SYNERGY™ was designed to allow for shortened DAPT and why it is a superior choice over BMS for short DAPT in elderly patients.

When we challenge the status quo,
we advance patient outcomes.